KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)].

E de Azambuja, M Piccart-Gebhart, S Fielding, J Townend, D W Hillman, M Colleoni, R Roylance, C M Kelly, J Lombard, S El-Abed, A Choudhury, L Korde, M Vicente, S Chumsri, R Rodeheffer, S L Ellard, A C Wolff, J Holtschmidt, I Lang, M Untch, F Boyle, B Xu, G Werutsky, J Tujakowski, C-S Huang, N B Baruch, J Bliss, A Ferro, J Gralow, S-B Kim, J R Kroep, I Krop, S Kuemmel, R McConnell, L Moscetti, A S Knop, F van Duijnhoven, H Gomez, D Cameron, S Di Cosimo, R D Gelber, A Moreno-Aspitia

ESMO Open 9(11) 103938

PMID39418883
PMCIDPMC11532431
DOI10.1016/j.esmoop.2024.103938
发表日期2024-10-17
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

BACKGROUND: Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastatic HER2-positive breast cancer. Here we present the final 10-year analysis of the ALTTO trial. PATIENTS AND METHODS: The ALTTO trial (NCT00490139) is a prospective randomized, phase III, open-label, multicenter study that investigated the role of adjuvant chemotherapy and trastuzumab alone, in combination or sequentially with lapatinib. The primary endpoint was disease-free survival (DFS) and secondary endpoints included overall survival (OS), time to distant recurrence and safety. RESULTS: Overall, 6281 patients with HER2-positive early breast cancer were included in the final efficacy analysis in three treatment groups: trastuzumab (T), lapatinib + trastuzumab (L + T) and trastuzumab followed by lapatinib (T→L). Baseline characteristics were well balanced between groups. At a median follow-up of 9.8 years, the addition of lapatinib to trastuzumab and chemotherapy did not significantly improve DFS nor OS. The 10-year DFS was 77% in T, 79% in L + T and 79% in T→L, and the 10-year OS was 87%, 89% and 89%, respectively. The incidence of any cardiac event was low and similar in the three treatment groups. CONCLUSIONS: With a longer follow-up, no significant improvement was observed in DFS in patients treated with dual anti-HER2 blockade with lapatinib + trastuzumab compared to trastuzumab alone. The 10-year survival rates for the combination group are consistent with other studies that have explored dual anti-HER2 therapy.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 2

Figure 2 Disease-free and overall survival in the inten tion to treat population. (A) Disease-free survival in the intention-to-treat population. (B) Overall survival. CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; Lap + Tras, lapatinib + trastuzumab; Tras: trastuzumab; Tras→Lap: trastuzumab followed by lapatinib.

A

Disease-free survival

Figure 2 · Panel A

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

Overall survival

Figure 2 · Panel B

quality_warning 待 EXE 对齐 预期 3 条 已提取 1 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 3 条,实际恢复 1 条
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 CONSORT diagram. IDMC, Independent Data Monitoring Committee; Lap, lapatinib; Lap + Tras, lapatinib + trastuzumab; Tras, trastuzumab; Tras→Lap, trastuzumab followed by lapatinib.
非 KM Figure